Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) PT at $25.60

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) have received a consensus rating of "Moderate Buy" from the sixteen analysts that are covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $25.60.

A number of equities analysts have recently commented on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Raymond James reaffirmed a "market perform" rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 10th. HC Wainwright reissued a "buy" rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Finally, StockNews.com downgraded ACADIA Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, November 14th.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, CFO Mark C. Schneyer sold 10,259 shares of the business's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $172,453.79. Following the sale, the chief financial officer now owns 53,302 shares in the company, valued at approximately $896,006.62. The trade was a 16.14 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider James Kihara sold 4,073 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total value of $68,467.13. Following the completion of the transaction, the insider now directly owns 19,863 shares in the company, valued at $333,897.03. This represents a 17.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,661 shares of company stock valued at $414,551 in the last ninety days. Corporate insiders own 28.30% of the company's stock.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Principal Financial Group Inc. boosted its holdings in ACADIA Pharmaceuticals by 67.8% in the third quarter. Principal Financial Group Inc. now owns 129,551 shares of the biopharmaceutical company's stock valued at $1,992,000 after purchasing an additional 52,340 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of ACADIA Pharmaceuticals by 1.1% in the third quarter. Geode Capital Management LLC now owns 2,875,540 shares of the biopharmaceutical company's stock worth $44,234,000 after buying an additional 30,826 shares during the last quarter. Barclays PLC grew its holdings in ACADIA Pharmaceuticals by 126.2% during the third quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock worth $4,269,000 after acquiring an additional 154,854 shares during the period. State Street Corp raised its position in ACADIA Pharmaceuticals by 3.0% during the third quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company's stock valued at $91,878,000 after acquiring an additional 173,084 shares in the last quarter. Finally, Iron Triangle Partners LP acquired a new position in ACADIA Pharmaceuticals in the third quarter valued at approximately $11,535,000. Institutional investors and hedge funds own 96.71% of the company's stock.

ACADIA Pharmaceuticals Trading Up 1.7 %

Shares of NASDAQ ACAD traded up $0.31 during midday trading on Thursday, hitting $18.66. The company's stock had a trading volume of 30,822,723 shares, compared to its average volume of 1,707,898. The business's 50 day moving average is $16.73 and its two-hundred day moving average is $16.37. ACADIA Pharmaceuticals has a 12-month low of $14.15 and a 12-month high of $31.10. The firm has a market cap of $3.10 billion, a P/E ratio of 23.92 and a beta of 0.40.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.06. The firm had revenue of $250.40 million during the quarter, compared to analyst estimates of $248.83 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The business's revenue was up 18.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.40) earnings per share. On average, analysts predict that ACADIA Pharmaceuticals will post 0.73 earnings per share for the current fiscal year.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.